Orthocell Limited OCC.AX · Stock Open Orthocell Limited in new tab
Analyst price targets
Recent rating changes, newest first
Orthocell Limited Analysis (OCC.AX)
Is Orthocell Limited a good investment? Orthocell Limited (OCC.AX) is currently trading at 0.6900 AUD. Market analysts have a consensus price target of 1.14 AUD. This suggests a potential upside from current levels.
Earnings Schedule: Orthocell Limited is expected to release its next earnings report on Feb. 19, 2027. The market consensus estimate for Forward EPS is -0.02.
Investor FAQ
Does Orthocell Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Orthocell Limited?
Orthocell Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Feb. 19, 2027. The company currently has a trailing EPS of -0.05.
Company Profile
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for bone, nerve, tendon, muscle, or scar tissue, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Community Discussion